Today: 29 January 2026
Subscribe
Browse Category

TSX:PSLV News 2 January 2026 - 12 January 2026

Silver price stock SLV jumps nearly 7% as Fed probe headlines push silver to fresh records

Silver price stock SLV jumps nearly 7% as Fed probe headlines push silver to fresh records

New York, January 12, 2026, 10:27 AM EST — Regular session Shares of iShares Silver Trust (SLV), widely used to track silver prices, jumped roughly 6.9% to $77.40 in early trading Monday. Volume surged sharply as the rally in silver pushed gains across ETFs and mining stocks. This rally isn’t just another metals bounce. Traders interpret the latest Washington headlines…
12 January 2026
·······
Silver ETFs jump in premarket as spot silver hits one-week high; SLV, SIVR in focus ahead of U.S. jobs data

Silver ETFs jump in premarket as spot silver hits one-week high; SLV, SIVR in focus ahead of U.S. jobs data

New York, Jan 6, 2026, 06:37 EST — Premarket U.S.-listed silver ETFs rose in premarket trade on Tuesday after spot silver climbed to a one-week high, keeping precious metals in focus ahead of key U.S. jobs data. iShares Silver Trust (SLV) was up 2.3% at $70.66, while abrdn Physical Silver Shares ETF (SIVR) gained 2.7% to $74.49. StockAnalysis The early…
6 January 2026
·······
Silver price today: SLV jumps 4% as spot silver rallies again in early 2026 trade

Silver price today: SLV jumps 4% as spot silver rallies again in early 2026 trade

NEW YORK, January 2, 2026, 10:04 ET — Regular session iShares Silver Trust (SLV) rose $2.57, or 4.0%, to $66.99 in morning New York trading on Friday, the first U.S. session of 2026. Spot silver was up 3.4% earlier on Friday after hitting an all-time high of $83.62 on Monday, Reuters reported. “Bulls seem to be drawing strength from geopolitical…
2 January 2026
·········

Stock Market Today

  • Teva Pharmaceutical Industries: Assessing Value After 79% One-Year Surge
    January 29, 2026, 3:52 PM EST. Teva Pharmaceutical Industries (TEVA) shares have jumped 79.1% over the past year, raising questions about current valuation at around $33.21. Despite the price rally, a Discounted Cash Flow (DCF) analysis indicates the stock trades at roughly 49.1% below its intrinsic value estimate of $65.20 per share, suggesting it remains undervalued. TEVA's latest twelve-month free cash flow stood at $1.12 billion, with analysts projecting growth to $4.58 billion by 2030. The company scored 2 out of 6 in Simply Wall St's valuation check, signaling some caution. This data provides investors a mixed picture: strong recent gains tempered by underlying value metrics pointing to potential investment opportunity in this large generic and specialty pharmaceutical firm.
Go toTop